

Friday April 22nd

Poster session: Pathogenesis, Antivirals, Clinical manifestations, Immunology, Vaccines, Diagnostics

Highlighted posters

Poster #	Name of presenter	Title	Session	
H-19	James Brien	Mouse model of antibody-enhanced Dengue virus infection	Pathogenesis	
H-20	Andrea Trujillo Correa	USE OF BIOINFORMATICS TO IDENTIFY INHIBITORS OF DENGUE VIRUS NS5-METHYLTRANSFERASE	Antivirals	
H-21	Benedito Antonio Fonseca Lopes	Dengue neurological disease is most likely due to virus infection	Clinical	<b>Poster Withdrawal</b>
H-22	Carolina de La Guardia	Antiviral activity of plant extracts and essential oils from Panamanian flora against dengue virus	Antivirals	
H-23	Daniel N. Streblow	Characterization of Immunotherapeutic Efficacy During Chikungunya Virus Infection of Rhesus Macaques	Pathogenesis	
H-24	Daniela Weiskopf	DENV-specific CD4 T-cells dominantly recognize capsid and display cytotoxic phenotypes	Immunology	
H-25	Davis Beltran	Expression of ligands of NKG2D and DNAM-1 receptors by dengue infected cells and activation of NK cells cocultured with these cells	Immunology	
H-26	Dhanasekaran Govindarajan	A Novel Combined Vaccine Approach against Dengue - A Pre-clinical Evaluation	Vaccines	
H-27	Dimelza Arauz	Comparison between the sensitivity of indirect methods to detect antibodies against Chikungunya virus	Diagnostics	
H-28	Douglas Widman	Strategy to measure DENV epitope-specific neutralizing antibody responses	Immunology	
H-29	Eduardo Ramirez Vallejo	Electrocardiographic alterations in patients with chikungunya fever from Sucre, Colombia: A 42-case series	Clinical	

<b>H-30</b>	Fernanda M de C Araújo	First documented cases of ZIKA virus Infection in Ceara, Brazil	Clinical
<b>H-31</b>	Giselle Barbosa Lima	DENGUE-ACTIVATED PLATELETS MODULATE MONOCYTE ACTIVATION THROUGH LIPID DROPLETS BIOGENESIS	Pathogenesis
<b>H-32</b>	Guillermo J Lagos Grisales	Post-chikungunya chronic inflammatory rheumatism: results from a retrospective follow-up study of 283 adult and children cases in La Virginia, Risaralda, Colombia	Clinical
<b>H-33</b>	Henry Puerta-Guardo	Flavivirus NS1 proteins differentially modulate endothelial permeability via the endothelial glycocalyx and intercellular junctions	Pathogenesis
<b>H-34</b>	Jael Miranda	Dengue patient sera factors effect over primary endothelium cell cultures	Pathogenesis
<b>H-35</b>	Jesica Swanstrom	Mapping antibody responses to a tetravalent dengue vaccine candidate (TDV)	Vaccines
<b>H-36</b>	Jessica Plante	Mapping the Impact of DENV-1 Genotypic Variation on Antibody Neutralization	Immunology
<b>H-37</b>	Karina R. Morales Gonzalez	Improving specificity of DENV E proteins through synthetic sequence redesign.	Diagnostics
<b>H-38</b>	Laura White	Next generation dengue vaccines with reduced potential for enhancement?	Vaccines
<b>H-39</b>	Priscila Castanha	Kinetics of dengue infection enhancing activity in Brazilian infants	Immunology
<b>H-40</b>	Patricia Sequeira	Systemic dissemination of Zika virus infection during an outbreak in Rio de Janeiro, Brazil	Diagnostics

### Regular posters

<b>R-76</b>	Adrienne Guignard	Modelling to inform dengue clinical trial design and interpretation	Vaccine
<b>R-77</b>	Shehana Tahir	Prevalence of post-Chikungunya Chronic Inflammatory Rheumatism: A Systematic Review and Meta-Analysis	Clinical

R-78	Alienys Izquierdo	ROLE OF THE CROSS-REACTIVE ANTIBODIES INDUCED BY DIII-C PROTEINS ON DENGUE INFECTION ENHANCEMENT.	Pathogenesis	
R-79	Ana B. Perez	DENGUE VIRUS NS1 PROTEIN REGIONS AS TARGET OF IMMUNE RESPONSE	Pathogenesis	
R-80	Andrea Trujillo Correa Angel Ambrocio AH	USE OF BIOINFORMATICS TO IDENTIFY INHIBITORS OF DENGUE VIRUS NS5-METHYLTRANSFERASE	Antivirals	
R-81		The $\beta$ 4 subunit of Cav1.2 Channels in Cardiac Cells Upregulates Interferon-related-Genes and Inhibits Dengue Virus Infection	Immunology	
R-82	Barreto Debora	Immunocompetent Murine Model for the Pathogenesis Study of Dengue Viruses	Pathogenesis	
R-83	Benedito Antonio Lopes da Fonseca	Dengue neurological disease is most likely due to virus infection	Clinical	<b>Poster Withdrawal</b>
R-84	Berta Nelly Restrepo	Frequency of dengue infection in patients with neurological disease	Clinical	
R-85	Betzana Zambrano	Adaptability of WHO Dengue Guidelines for a vaccine efficacy trial	Vaccine	
		Long-Term Safety of a CYD-TDV Dengue Vaccine in Asia	Vaccine	
R-86	Betzana Zambrano	Dengue		
R-87	Carolina De La Guardia	Endemic Countries		
R-88	Cassia Fernanda Estofolete	Identification of peptides with binding activity to DENV-2 E glycoprotein	Antivirals	
R-89	Cassia Fernanda Estofolete	Fever relevance in patients with dengue	Clinical	
R-90	Rosa Cetina-Trejo	DENGUE IN KIDNEY TRANSPLANT RECIPIENTS: REPORT OF 11 CASES FROM A CENTER	Clinical	
R-91	Cesar Lam	Early detection of dengue virus by capture IgE ELISA test	Diagnostic	
R-92	Courtney Veilleux Daniel Arellanos-Soto	Dengue and Leptospira coinfection- A case study.	Clinical	
		Dengue Infection Compromises the Survival and Function of Human Monocytes: Implications in Transmigration	Pathogenesis	
R-93		Evaluation of interferon response profiles induced by different Dengue viral strains isolated from Mexican patients	Immunology	
R-94	Daniele Cristina Passos da Rocha	Dengue virus NS1 protein increases dehydrogenase glyceraldehyde – 3 – phosphate (GAPDH) activity	Pathogenesis	

<b>R-95</b>	Danielle Malta Lima	Dengue clinical profile in the last four years in Fortaleza	Clinical-Diagnostic
<b>R-96</b>	ADRIANA ROLIM	Antiviral activity of the Acrocomia aculeata against the dengue virus	Antivirals
<b>R-97</b>	Danilo Casimiro	Phase I Safety/Immunogenicity of a Tetravalent Subunit Dengue Vaccine	Vaccine
<b>R-98</b>	David Alejandro Calle	COMPARISON OF DIAGNOSTIC TESTS FOR DENGUE, CHIKUNGUNYA AND WEST NILE	Diagnostic
<b>R-99</b>	Diana Patricia Londono	DENGUE-CHICUNGUNYA COINFECTION IN QUINDIO, COLOMBIA, IN 2015	Clinical
<b>R-100</b>	Eduardo Nascimento	IgG RESPONSE TARGETING A DV3-NS1 EPI TOPE ASSOCIATES WITH PROTECTION AGAINST DENGUE SEVERITY	Immunology
<b>R-101</b>	Elizabeth A. Dietrich	Transmission potential of Takeda's dengue vaccine candidates in Aedes albopictus	Vaccine
<b>R-102</b>	Emily Gallichotte	Diversity across DENV2 type-specific antibody epitopes	Immunology
<b>R-103</b>	Federico Perdomo Celis	DYSFUNCTION OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN NATURALLY INFECTED CHILDREN	Pathogenesis
<b>R-104</b>	Fernanda M. C. de Araujo	Neurological manifestations of DENV in fatal cases Ceará, Brasil	Clinical
<b>R-105</b>	Fernanda Cunha Jácome	Morphological and Viremia Analysis of Mice Infected with Dengue 2	Pathogenesis
<b>R-106</b>	Gissel Garcia	PERSISTENCE OF SYMPTOMS POST DENGUE INFECTION: ASSOCIATION WITH IMMUNOLOGICAL MARKERS	Pathogenesis
<b>R-107</b>	Harrison Herrera Delgado	DETECTION OF PLASMA TUMOR NECROSIS FACTOR- $\alpha$ : A COMPARISON IN PEDIATRIC DENGUE	Diagnostic
<b>R-108</b>	Heather Friberg	Cellular immune responses TO a tetravalent dengue purified inactivated vaccine	Vaccine
<b>R-109</b>	Izabella Andrade Batista	DESIGNING CHIMERICAL DENGUE PROTEINS APPLIED TO MULTISEROTYPE VACCINES	Vaccine
<b>R-110</b>	James D. Brien	Immune system based therapeutics protect against antibody enhanced Dengue immunopathogenesis	Antivirals
<b>R-111</b>	Jared Pitts	Monitoring dengue RNA synthesis/decay in the presence of viral inhibitors	Antivirals
<b>R-112</b>	Jessie Pari	EVALUATION OF A COMERCIAL ELISA METHOD FOR CHIKUNGUNYA VIRUS EN PERÚ	Diagnostic
<b>R-113</b>	Jesús Vizoso-Quintana,	Is Caspase-1 required for early secretion of Il-1b Dengue infection?	Immunology

<b>R-114</b>	Joanna L. Miller	Effects of iminosugars on expression and function of macrophage receptors important in dengue virus disease	Antivirals
<b>R-115</b>	Jorge Andrés Castillo	Monocyte early and late response upon DENV infection	Immunology
<b>R-116</b>	Julio García-Cordero	NS3 protein of Dengue is located in MRD of HMEC-I.	Pathogenesis
<b>R-117</b>	Kame Alberto Galan Huerta	Clinical manifestations of Chikungunya virus infection in Mexican population	Clinical
<b>R-118</b>	Karla Fabiane Lopes de Melo	Evaluation of the miRNA pathway activity during DENV-4 infection	Immunology
<b>R-119</b>	Katerine Marin	Platelet activation in dengue patients, Colombia	Severity Markers
<b>R-120</b>	Kenneth Plante	The Collaborative Cross Identifies Genetic Determinants of Chikungunya Pathology	Pathogenesis
<b>R-121</b>	Leidy Lorena García	Curcumin assessment on ARN polymerase of Dengue Virus 2	Antivirals
<b>R-122</b>	Leticia Castillo	Dengue-Duo Validation for diagnosis/surveildengue in Guatemala	Diagnostic
<b>R-123</b>	Leyi Lin	Tetavalent dengue heterologous prime-boost vaccination: One month Safety and Immunogenicity	Vaccine
<b>R-124</b>	Lisbeth Saenz	Development of Diagnostic Methods for Detecting Specific Genotypes of Chikungunya.	Diagnostic
<b>R-125</b>	Lucile Warter	Preclinical characterization of a tetavalent dengue purified inactivated vaccine candidate	Vaccine
<b>R-126</b>	Luisa Alvarado	Early indicators of dengue among children and adults, Puerto Rico	Severity Markers
<b>R-127</b>	Ma Isabel Salazar	Effect in vitro of thalidomide on DENV infected cells	Immunology
<b>R-128</b>	Margarita Ochoa Diaz	Dengue, Zika or Chikungunya, another arbovirus between us	Clinical
<b>R-129</b>	Michael Rossman	Cryo-electron microscopy characterization of Chikungunya virus interacting with monoclonal antibodies	Immunology
<b>R-130</b>	Min Li	Elicitation of dengue virus neutralizing antibodies with divergent subunit vaccines	Vaccine
<b>R-131</b>	Moisés León-Juarez	Recombinant DENV NS2B protein alters membrane permeability in different models membranes	Pathogenesis
<b>R-132</b>	Monique R Queiroz Lima	Alternative Production of Recombinant Envelope Tetra-Epitope Antigen Produced In Transplastomic Lettuce	Diagnostic

<b>R-133</b>	Monique Trugilho	Quantitative proteomic analysis of HepG2 cell expressing the Dengue Virus NS1 protein	Pathogenesis
<b>R-134</b>	Natal Santos de Silva	Risk factors associated with hospitalization for dengue	Clinical
<b>R-135</b>	Nathália Furlan Barbosa	Test value of the tourniquet for patients suspected dengue	Diagnostic
<b>R-136</b>	Owen Bryan-Marrugo	Modulation of Cholesterol Pathway has Significant Effect on the Antiviral Capacity of Liver Cells against Dengue Virus	Antivirals
<b>R-137</b>	Ana Fernandez-Sesma	Phenotypical differences of DENV-2 and DENV-4 in human primary systems	Immunology
<b>R-138</b>	Robert Hontz	Antibody Avidity and Subclass in Symptomatic and Inapparent Dengue Infections	Immunology
<b>R-139</b>	Rosa Ramírez	Recombinant ns3 protein from dengue-2 induce functional cell-mediated immunity in mice	Vaccine
<b>R-140</b>	Silvia Fonseca	Dengue patients in a private hospital in Ribeirao Preto, Brasil	Clinical
<b>R-141</b>	Stefan W. Metz	Particulate display of DENV-E proteins induces robust neutralizing antibody responses.	Vaccine
<b>R-142</b>	Tereza Magalhaes	Dengue virus growth in mosquito and mammalian cells with distinct immune phenotypes	Immunology
<b>R-143</b>	Usha Nivarthi	Mapping human neutralizing antibody responses to dengue virus serotype 4	Immunology
<b>R-144</b>	Victor R. DeFilippis	Anti-Arboviral Efficacy of Innate Immune Activation by Novel Small Molecules	Antivirals
<b>R-145</b>	Virginia Nunez Samudio	A case from panama of dengue coexistent with hantavirus pulmonary syndrome	Clinical
<b>R-146</b>	Wendy Murillo	Evaluation of a Commercial Serologic Diagnostic Test for Chikungunya Virus	Diagnostic
<b>R-147</b>	Yerly Useche	STING/IRF3 polymorphisms are associated with Dengue severity in Colombian children	Pathogenesis
<b>R-148</b>	Mariana Ruiz Silva	Mechanisms of MCP-1 upregulation upon CHIKV infection in human peripheral blood mononuclear cells	Immunology

94 posters